Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital Boosts Artiva Biotherapeutics Stake to 33.7% with $100M Offering Investment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.58
Mkt Cap
$259.525M
52W Low
$1.47
52W High
$14.53
52W Position info
620% above low
Off High info
27% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $1.47.

Summary

RA Capital Management, a major institutional investor, significantly increased its stake in Artiva Biotherapeutics by purchasing nearly $100 million in common stock and pre-funded warrants as part of the company's recent public offering, raising its beneficial ownership to 33.7%.


Key Events · Ownership and Investor Activity · ARTV

  • Major Institutional Investment

    RA Capital Management, L.P. purchased approximately $100 million in common stock and pre-funded warrants on May 11, 2026.

  • Increased Ownership Stake

    This transaction increases RA Capital's beneficial ownership to 33.7% of Artiva Biotherapeutics' common stock.

  • Participation in Public Offering

    The purchase was made as part of the company's recent public offering, demonstrating strong institutional support following positive clinical data.


Analysis · ARTV · Life Sciences

This Schedule 13D/A confirms a substantial $100 million investment by RA Capital Management, a major institutional investor, into Artiva Biotherapeutics' recent public offering. This significant capital injection, which increases RA Capital's beneficial ownership to 33.7%, follows the company's positive initial clinical data for its lead program, AlloNK, and provides strong validation of its prospects. The investment represents a critical vote of confidence from a key stakeholder, especially after the company's recent capital raise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $10.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.5M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.83 info
Change: -$0.390 (-9%) info
Market Cap: $189.326M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $3.83 info
Change: -$0.260 (-6%) info
Market Cap: $189.326M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $3.83 info
Change: -$2.47 (-39%) info
Market Cap: $189.326M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $3.83 info
Change: -$3.42 (-47%) info
Market Cap: $189.326M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $3.83 info
Change: -$7.75 (-67%) info
Market Cap: $189.326M info